H J Ju, H J Park, I H Choi, K H Lee, M Y Kwon, C J Park
Issues - Luglio 2022
H J Ju, H J Park, I H Choi, K H Lee, M Y Kwon, C J Park
S Takamura, S Sugai, R Taguchi, Y Teraki
Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue
J Dermatol. 2020 Mar;47(3):290-294Jennifer Aileen Ang Tangtatco, Irene Lara-Corrales
Update in the management of pediatric psoriasis
Curr Opin Pediatr. 2017 Aug;29(4):434-442J Zitouni, A-C Bursztejn, A Belloni Fortina, A Beauchet, V Di Lernia, A Lesiak, J Thomas, Z Topkarci, N Murashkin, P Brzezinski, T Torres, A Chiriac, C Luca, T McPherson, M Akinde, A Maruani, R Epishev, H Vidaurri de la Cruz, P C Luna, M Amy de la Bretêque, A Lasek, E Bourrat, M Bachelerie, S Mallet, M Steff, A Bellissen, I Neri, E Zafiriou, J M P A van den Reek, E Sonkoly, S K Mahil, C H Smith, C Flohr, H Bachelez, E Mahé, Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.)
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)
J Eur Acad Dermatol Venereol. 2022 Jun 24Hee-Geun Jo, Hyehwa Kim, Donghun Lee
Oral administration of East Asian herbal medicine for inflammatory skin lesions in plaque psoriasis: A systematic review, meta-analysis, and exploration of core herbal materials
Nutrients. 2022 Jun 12;14(12):2434T Okamoto, M Kawai, Y Ogawa, S Shimada, T Kawamura
Artificial intelligence for the automated single-shot assessment of psoriasis severity
J Eur Acad Dermatol Venereol. 2022 Jun 23Christopher E M Griffiths, Melinda Gooderham, Jean-Frederic Colombel, Tadashi Terui, Ana P Accioly, Gaia Gallo, Danting Zhu, Andrew Blauvelt
Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 17 clinical trials with over 18,000 patient-years of exposure
Dermatol Ther (Heidelb). 2022 May 27. Online ahead of printKristian Reich, Lars Erik Kristensen, Saxon D Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham
Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104Vivaswath S Ayyar, Jong Bong Lee, Weirong Wang, Meghan Pryor, Yanli Zhuang, Thomas Wilde, An Vermeulen
Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in skin informs anti-IL17A drug development in psoriasis
Front Pharmacol. 2022 Apr 25;13:862291Craig Leonardi, Baojin Zhu, William N Malatestinic, William J Eastman, Jiaying Guo, Mwangi J Murage, Casey Kar-Chan Choong, Russel Burge, Andrew Blauvelt
Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: Results from IBM MarketScan® databases
Adv Ther. 2022 May 16. Online ahead of printEmilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535N Bernardini, N Skroza, E Tolino, A Marchesiello, A Mambrin, V Balduzzi, S Michelini, P Maddalena, S Volpe, I Proietti, C Potenza
HIV positive patient treated with ixekizumab
Clin Ter. 2022 May 25;173(3):195-197Andrew Blauvelt, Nianwen Shi, Mwangi J Murage, Scott A Kern, Najwa Somani, Russel Burge, Terri L Ridenour, Carolyn R Lew, Nicole M Zimmerman, Baojin Zhu